摘要
目的:探讨参芪扶正注射液用于乳腺癌术后辅助化疗的临床效果。方法:选取2014年9月至2015年10月在西安交通大学第一附属医院乳腺外科及宝鸡市中心医院乳腺科行乳腺癌改良根治手术的乳腺癌患者384例,按随机数字表法分为观察组和对照组,每组192例。对照组实施TA方案化疗,观察组实施TA方案联合参芪扶正注射液辅助化疗。对比两组患者血清肿瘤标志物水平、体征(神疲、懒言、乏力、气短、自汗)积分、癌因性疲乏(躯体疲乏、精神疲乏、情绪状态)量表积分、不良反应发生率及术后复发转移率,并采用卡氏评分法对患者的生活质量进行评估。结果:化疗后两组患者血清癌胚抗原(CEA)及糖类抗原CA153、CA125水平均较化疗前有明显改善(均P<0.05),但组间比较差异无统计学意义(P>0.05)。观察组体征积分、癌因性疲乏量表积分及不良反应发生率均显著低于对照组(均P<0.05),生活质量改善率显著高于对照组(P<0.05)。随访18个月,两组术后复发转移率比较,差异无统计学意义(P>0.05)。结论:参芪扶正注射液辅助乳腺癌术后化疗可改善患者体征,减轻癌因性疲乏及化疗毒副作用,提高患者的生活质量。
Objective： To investigate the effect of Shenqi Fuzheng injection（SFI）on postoperative chemotherapy for breast cancer. Methods： 384 patients with breast cancer treated in our hospital from Sep-tember 2014 to October 2015 were selected and randomly divided into an observation group and a control group,with 192 cases in each group. The patients in the control group received TA chemotherapy,and those in the observation group were treated as the control group with addition of SFI. The serum tumor indicators levels,clinical symptoms,cancer-related fatigue（CRF）,the incidence of adverse reactions,recurrence rate and the quality of life（QOL）were observed and compared. Results： After chemotherapy,all patients had improved CEA,CA153 and CA125 levels,but there was no significant difference between the two groups（P〈0. 05）. The clinical symptoms sores,CRF scale scores,and the incidence of adverse events in the observation group were markedly lower than those in the control group,whereas the percentage of improved QOL was higher（P〈0. 05）. After 18 months of follow-up,no significant difference was noted in the recurrence rate between the two groups（P〈0. 05）. Conclusion： SFI might be an effective adjuvant to chemotherapy for breast cancer. It could improve clinical symptoms,attenuate CRF,decrease the incidence of adverse events and increase patients＇ QOL.
出处
《广西医科大学学报》
CAS
2017年第12期1734-1737,共4页
Journal of Guangxi Medical University
基金
陕西省宝鸡市科技计划项目(No.16SFGG3-8)
关键词
参芪扶正注射液
乳腺癌
术后化疗
Shenqi Fuzheng injection
breast cancer
postoperative chemotherapy
